SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| Cetraxal plus | 3,0.25 mg/ml,mg/ml | Ear drops, solution · Auricular use | 15 Single Dose Container | SAR 41.30 | NCE · Prescription | Laboratories SALVAT, S.A | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|
| OTOVEL | EQ 0.3% BASE;0.025% | solution/drops · otic | LAB SALVAT | Prescription | 29 Apr 2016 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| OTIXAL | 02459655 | 0.3 % / W/V; 0.025 % / W/V | SOLUTION · OTIC | MEDEXUS PHARMACEUTICALS INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| NHS Drug Tariff | Ciprofloxacin 3mg/ml / Fluocinolone acetonide 0.25mg/ml ear drops 0.25ml unit dose preservative free | £6.01 | 15 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.